Rogue tweet nearly triples HemoGenyx stock price

26 February 2018

HemoGenyx Pharmaceuticals (LSE: HEMO), a bone marrow and blood stem cell transplantation specialist based in the UK, has released a statement after an elliptical tweet this morning sent the firm’s share price skyrocketing.

Referring to the “premature disclosure which the company regrets,” HemoGenyx explained that early data had shown that “CDX bi-specific antibodies are capable of attacking and eliminating the blood cancer acute myelogenous leukemia (AML) in vitro.”

The tweet, which hinted at a clinical breakthrough, triggered a day of heightened trading for investors in the firm, leading to a 170% rise in its share price.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK